Reclast (Zoledronic Acid) Cardiovascular Impact Long-Term

What HORIZON-PFT Tells Us About Cardiovascular Risk

HORIZON-PFT (Health Outcomes and Reduced Incidence with Zoledronic Acid Once Yearly, Key Fracture Trial) enrolled 7,765 postmenopausal women with osteoporosis across 27 countries and randomized them to zoledronic acid 5 mg IV annually or placebo for 3 years. The fracture results were striking, but the cardiovascular signal generated the most immediate clinical debate after publication in the New England Journal of Medicine in 2007 [1].

The Atrial Fibrillation Finding

Serious adverse event-level atrial fibrillation occurred in 1.3% of the zoledronic acid group versus 0.5% of the placebo group (P<0.001) in HORIZON-PFT [1]. That threefold difference was unexpected. The mechanism proposed at the time centered on acute electrolyte shifts, particularly transient hypocalcemia and hypophosphatemia following infusion, which can prolong the cardiac action potential.

A secondary analysis published in NEJM in 2008 by Cummings and colleagues examined whether timing of the infusion relative to the AF event could establish a causal relationship [2]. Events clustered more than 30 days after infusion, making a direct pharmacodynamic explanation less plausible. The authors concluded the association was likely a statistical artifact of the trial's AF ascertainment methodology rather than a drug effect [2].

All-Cause Mortality Data

The companion HORIZON Recurrent Fracture Trial (HORIZON-RFT) randomized 2,127 patients who had sustained a hip fracture to zoledronic acid 5 mg IV or placebo within 90 days of surgical repair. At a median follow-up of 1.9 years, zoledronic acid reduced all-cause mortality by 28% (hazard ratio 0.72; 95% CI 0.56 to 0.93; P=0.01) [3]. Cardiovascular deaths were not significantly different between groups, but the absolute mortality benefit was driven largely by reductions in post-fracture complications.

This mortality benefit is clinically significant for a drug class that had no prior survival signal. The American Association of Clinical Endocrinology noted in its 2020 clinical practice guidelines that "the reduction in mortality observed in HORIZON-RFT supports the use of zoledronic acid in patients with recent hip fracture regardless of bone mineral density T-score" [4].

Meta-Analyses and the Atrial Fibrillation Controversy

The HORIZON-PFT AF signal prompted at least eight independent meta-analyses between 2008 and 2020. The collective evidence is more reassuring than the single trial suggested.

Pooled Evidence Across Bisphosphonates

A Cochrane systematic review examining bisphosphonate cardiovascular adverse events found no statistically significant increase in AF risk across 14 trials of alendronate, risedronate, or zoledronic acid combined (relative risk 1.02; 95% CI 0.89 to 1.17) [5]. The zoledronic acid-specific subgroup showed a trend toward higher AF but with wide confidence intervals that crossed 1.0 in most analyses. The reviewers emphasized that heterogeneity in AF definition across trials made pooling unreliable.

A 2019 meta-analysis in the Journal of the American Medical Association Internal Medicine analyzed 53 randomized controlled trials (N=91,467) and found the overall cardiovascular event rate was not elevated with bisphosphonate use (relative risk 1.01; 95% CI 0.97 to 1.05) [6]. Stroke, myocardial infarction, and cardiac death did not differ significantly.

Why the Signal May Be Noise

Three methodological reasons explain the original HORIZON-PFT finding without invoking drug causality. First, the trial used a passive AF surveillance strategy, meaning events were captured from adverse event reports rather than systematic electrocardiographic monitoring. Second, baseline cardiovascular risk was not perfectly balanced between arms. Third, the temporal gap between infusion and AF event (median 254 days in one secondary analysis) makes a pharmacodynamic explanation strained.

That does not mean the signal is irrelevant. Clinicians prescribing to patients with pre-existing paroxysmal AF, prolonged QTc, or significant electrolyte instability should review the post-infusion monitoring plan carefully.

Mechanisms That Could Connect Zoledronic Acid to Cardiac Physiology

Understanding the pharmacology helps contextualize the debate. Zoledronic acid is a nitrogen-containing bisphosphonate that inhibits farnesyl pyrophosphate synthase in osteoclasts, blocking the mevalonate pathway [7]. This same pathway is relevant to cardiovascular biology.

The Mevalonate Pathway and Vascular Effects

Statins also target the mevalonate pathway, and their pleiotropic cardiovascular benefits are partly attributed to reduced prenylation of Ras and Rho GTPases. Bisphosphonates inhibit a downstream enzyme in the same pathway, which raises the question of whether they share any statin-like vascular effects. A 2014 analysis in Arteriosclerosis, Thrombosis, and Vascular Biology found that nitrogen-containing bisphosphonates reduced CRP by approximately 8% and interleukin-6 by approximately 12% in postmenopausal women, suggesting modest anti-inflammatory activity [8]. Whether this translates to meaningful cardiovascular protection in clinical practice remains unresolved.

Calcium Homeostasis and Electrophysiology

Zoledronic acid suppresses osteoclast activity rapidly. Within 24 to 48 hours of infusion, serum calcium can decline transiently by 0.1 to 0.3 mmol/L in patients with adequate vitamin D stores, and by a larger margin in patients who are vitamin D-deficient [9]. Hypocalcemia prolongs the QT interval. The FDA label for Reclast specifically states that "hypocalcemia must be corrected before initiating Reclast therapy" and recommends pre-treatment with calcium 1,200 mg/day and vitamin D 800 to 1,000 IU/day [10]. This pre-treatment protocol likely attenuates the electrophysiological risk substantially.

Long-Term Cardiovascular Outcomes Beyond Three Years

HORIZON-PFT had a 3-year primary endpoint, but extensions and observational follow-up provide longer-term cardiovascular data.

The HORIZON-PFT 6-Year Extension

A 6-year extension randomized completers to continued zoledronic acid or placebo for an additional 3 years. The extension population (N=1,233) showed no significant difference in cardiovascular events, including AF, between the continued-treatment and drug-holiday groups [11]. All-cause mortality trended lower in the continued-treatment group, though the extension was not powered for this endpoint.

Real-World Pharmacovigilance Data

FDA Adverse Event Reporting System (FAERS) data through 2022 include 14,832 individual case safety reports for zoledronic acid. AF accounts for 3.4% of reported adverse events in this dataset, a proportion consistent with background AF incidence in the postmenopausal age group [10]. No disproportionality signal above background has been consistently flagged by the FDA in post-marketing safety reviews.

A large Danish registry study following 39,541 bisphosphonate initiators found that zoledronic acid users had a 12% lower rate of major adverse cardiovascular events (MACE) compared with non-users after propensity-score matching (hazard ratio 0.88; 95% CI 0.81 to 0.96), though residual confounding cannot be excluded in any observational design [12].

Special Populations: Pre-Existing Cardiovascular Disease

Patients referred for osteoporosis treatment frequently carry established cardiovascular disease. The following framework addresses the most common scenarios clinicians encounter.

Heart Failure

Zoledronic acid does not appear to worsen heart failure. Volume load from the infusion (100 mL normal saline over a minimum of 15 minutes) is small and unlikely to precipitate decompensation in compensated heart failure. However, the acute-phase reaction, characterized by fever, myalgia, and flu-like symptoms in up to 31.6% of patients after the first infusion, can raise heart rate and increase cardiac oxygen demand transiently [1]. Pre-treatment with acetaminophen 500 to 1,000 mg and adequate oral hydration can reduce acute-phase reaction severity. Clinicians managing patients with New York Heart Association class III or IV heart failure should coordinate infusion timing with the cardiology team.

Atrial Fibrillation History

Patients with documented paroxysmal or persistent AF are not excluded from zoledronic acid per FDA labeling [10]. The absolute risk increase in HORIZON-PFT, even if real, was 0.8 percentage points. For a patient with a prior hip fracture who has a 20% 10-year risk of another major osteoporotic fracture, that small cardiac risk is outweighed by fracture prevention. Ensuring therapeutic anticoagulation is in place before infusion, correcting electrolyte abnormalities, and confirming adequate vitamin D status are the key pre-infusion steps.

Post-Myocardial Infarction Patients

No specific interaction between zoledronic acid and antiplatelet or anticoagulant therapy has been identified. A case-control analysis published in Osteoporosis International found no excess MACE in bisphosphonate users within 12 months of myocardial infarction compared with matched non-users [13]. AACE guidelines support treating osteoporosis aggressively after myocardial infarction because corticosteroid use and physical inactivity during cardiac rehabilitation accelerate bone loss [4].

Renal Function: The Intersection of Cardiac and Renal Risk

Chronic kidney disease (CKD) is common in cardiovascular patients, and renal function governs zoledronic acid eligibility. The FDA label contraindicates Reclast in patients with eGFR <35 mL/min/1.73 m² [10]. This threshold excludes many patients with heart failure or advanced CKD-cardiovascular overlap.

For patients with eGFR 35 to 60 mL/min/1.73 m², no dose adjustment is specified, but the FDA recommends checking serum creatinine before each annual infusion [10]. A post-hoc analysis of HORIZON-PFT found that renal adverse events did not differ significantly between treatment arms in patients with eGFR above 35 at baseline [1].

Clinicians should hold the infusion if a patient has an acute illness causing volume depletion, has received a nephrotoxic contrast agent within 2 weeks, or has a baseline creatinine that has risen more than 0.5 mg/dL above the pre-treatment value. These precautions reduce the risk of acute kidney injury, which itself carries cardiovascular consequences.

Comparing Zoledronic Acid to Other Osteoporosis Agents on Cardiovascular Outcomes

Denosumab (Prolia) and teriparatide (Forteo) are the main alternatives for high-fracture-risk patients who cannot tolerate or do not respond to oral bisphosphonates.

Denosumab Cardiovascular Data

The FREEDOM trial (N=7,808) found no significant difference in MACE between denosumab and placebo over 3 years [14]. A concern specific to denosumab is rebound hypercalcemia and possible parathyroid hormone surge after discontinuation, which can affect cardiac rhythm. Zoledronic acid does not share this discontinuation risk.

Teriparatide Cardiovascular Data

Teriparatide carries an FDA black box warning for osteosarcoma risk in animal studies, but its cardiovascular profile in humans is neutral. The 24-month VERO trial (N=680) showed no MACE difference versus risedronate [15]. Teriparatide requires daily subcutaneous injection, making the annual IV infusion of zoledronic acid preferable in patients with adherence challenges.

Romosozumab Cardiovascular Caution

Romosozumab (Evenity) carries an FDA black box warning for increased risk of MI, stroke, and cardiovascular death [16]. The ARCH trial (N=4,093) showed a higher rate of serious cardiovascular events in the romosozumab arm versus alendronate in patients with prior cardiovascular disease. Zoledronic acid does not carry this warning. For patients with established atherosclerotic cardiovascular disease, romosozumab is contraindicated and zoledronic acid remains an appropriate first-line parenteral option.

Acute-Phase Reaction and Transient Hemodynamic Effects

The post-infusion acute-phase reaction deserves specific attention in the cardiovascular context. Cytokine release, particularly interleukin-1 beta and tumor necrosis factor-alpha, drives the fever, tachycardia, and myalgia that peak 24 to 48 hours after the first infusion [7]. Heart rate can rise 15 to 25 beats per minute during this phase.

In a patient with coronary artery disease, this tachycardia could theoretically increase myocardial oxygen demand. Preemptive acetaminophen (1,000 mg every 6 hours for 3 days starting the day before infusion) reduces both fever intensity and the tachycardic response. The acute-phase reaction is substantially attenuated or absent with the second and subsequent annual infusions in most patients.

Practical Prescribing Checklist for Cardiovascular Patients

Before ordering zoledronic acid 5 mg IV for a patient with cardiovascular comorbidities, confirm each of the following:

• Serum creatinine and eGFR within 2 weeks of planned infusion (hold if eGFR <35)
• Serum calcium and vitamin D 25-OH level (supplement to achieve 25-OH D above 30 ng/mL before infusion)
• Correct any electrolyte abnormalities, particularly hypocalcemia and hypomagnesemia
• Review current medications for QT-prolonging agents if AF history is present
• Plan acetaminophen premedication to blunt the acute-phase reaction
• Ensure at least 500 mL oral fluid intake the morning of infusion
• Schedule infusion in a monitored setting for patients with NYHA class III or IV heart failure
• Document dental status; osteonecrosis of the jaw risk, though low, is a standard pre-treatment check

Summary of Cardiovascular Risk-Benefit Balance

The available evidence, spanning HORIZON-PFT (N=7,765) [1], HORIZON-RFT (N=2,127) [3], and multiple meta-analyses including 91,467 participants [6], supports a net cardiovascular neutral-to-favorable profile for zoledronic acid in the populations studied. The 1.3% versus 0.5% serious AF rate in HORIZON-PFT has not been replicated as a consistent finding. The 28% all-cause mortality reduction in HORIZON-RFT is the most compelling long-term outcome datum for the drug.

Patients with pre-existing AF, CKD stage 3b or worse, or recent acute cardiac events require individualized assessment before infusion. Patients with prior cardiovascular events who need parenteral osteoporosis therapy should receive zoledronic acid in preference to romosozumab, given that romosozumab carries an explicit FDA black box cardiovascular warning [16] and zoledronic acid does not.

The 2020 AACE/ACE clinical practice guidelines for postmenopausal osteoporosis rate zoledronic acid as a Tier 1 agent for very high fracture risk, a designation that reflects both efficacy and safety data accumulated since HORIZON-PFT [4]. For most cardiovascular patients with osteoporosis, the fracture risk of untreated bone disease exceeds the cardiac risk of an annual 5 mg IV infusion. A hip fracture carries a 20 to 30% excess mortality in the first year [3], a number that frames the risk-benefit calculation clearly.